Antiviral Activity of Kagocel® in vitro Against Virus SARS-CoV-2
https://doi.org/10.37489/0235-2990-2020-65-3-4-3-6
Abstract
The antiviral activity of the drug Kagocel®, which has a high safety profile and proven efficacy for the prevention and treatment of influenza and AVRI as an interferon inducer, was studied against a new pandemic strain of SARS-CoV-2 in vitro in Vero C1008 cell culture. The results of the study revealed that at the addition of the substance Kagocel® at the concentration of 5000 pg/ml into the cell culture 1 h before the virus infection and 1 h after, there was 100% inhibition of the cytopathic activity of the virus. It was also found that Kagocel® at the dose of 5000 pg/ml effectively suppressed the reproduction of the SARS-CoV-2 virus, variant B, in Vero C1008 cell culture by 1.75 lg, the inhibition coefficient was 97.83 %.
About the Authors
S. Ya. Loginova
48 TSNII Ministry of Defence of the Russian Federation
Russian Federation
Sergiyev Posad
Russian Federation
Sergiyev Posad
V. N. Shchukina
48 TSNII Ministry of Defence of the Russian Federation
Russian Federation
Sergiyev Posad
Russian Federation
Sergiyev Posad
S. V. Savenko
48 TSNII Ministry of Defence of the Russian Federation
Russian Federation
Sergiyev Posad
Russian Federation
Sergiyev Posad
S. V. Borisevich
48 TSNII Ministry of Defence of the Russian Federation
Russian Federation
Sergiyev Posad
Russian Federation
Sergiyev Posad
References
1. Nikiforov V.V., Suranova T.G., Chernobrovkina T.Ya. et al. New Coronavirus Infection (Covid-19): Clinical and Epidemiological Aspects. The Russian Archives of Internal Medicine. 2020; 10 (2): 87-93. doi: 10.20514/2226-6704-2020-10-2-87-93
2. Li Guangdi, Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020; 19: 149-150. doi: 10.1038/d41573-020-00016-0.
3. Lythgoe M.P. et al. Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. Pharmacology and Therapeutics 2016; 164: 195-203. doi.org/10.1016/j.pharmthera.2016.04.012
4. Lythgoe M.P., Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends in Pharmacological Sciences 2020;https://doi.org/10.1016/j.tips.2020.03.006.
5. Sologub T.V., Tsvetkov V.V. Kagocel in the therapy of influenza and acute respiratory viral infections: Data analysis and systematization from the results of preclinical and clinical trials Therapeutic archive 2017; 89 (8): 113-119 [in Russian].
6. Borovskaya T. G. Preclinical and clinical evidence of safety of antiviral drug with immunomodulatory activity. Serbian Journal of Experimental and Clinical Research 2018; 3 (19): 271-276.
7. Fediakina I.T, Konopleva M.V., Proshina E.S., Linnik E.V., Nikitina N.I. Antiviral effect of «Kagocel» substance in vitro on influenza viruses H1N1, H1N1pdm09 and H3N2. Problems of Virology 2019; 64 (3): 125-131. doi: 10.18821/0507-4088-2019-64-3-125-131
8. Zarubaev V. V., Garshinina A. V., Slita A. V., Belyaevskaya S. V., Lavrentieva I. N. Antiviral Activity of Kagocel® on the Model of Experimental Lethal Influenza Infection. Antibiotiki i khimio- ther 2020; 65 (1-2): 3-7. [in Russian].
9. Galegov G.A., Narovlianskii A.N., Sarymsakov A.A., Mezentseva M. V., Polonskii V. O., Gomes L.A., Nesterenko V.G., Ershov F.I. The effect of Kagocel on herpes virus reproduction. Problems ofVirology 2002; 47 (4): 42-44. [in Russian]
10. Kharlamova F.S., Uchaikin V.F., Bevza S.L., Ershov F.I., Nesterenko V.G., Sergeeva E.M. et. al. Clinical efficacy of Kagotsel in treatment for acute respiratory virus infections (ARVI) in children with constrictive laryngotracheitis. Detskie infekcii 2008; 4: 28-35 [in Russian].
11. Savenkova M.S., Isaeva E.I., Karashtina O.V., Shabat M.B., Kraseva G.N. et al. Comparative analysis of treatment of ARVI in the 2015¬2016 epidemic season based on the results of the multiplex PCR-RT diagnostics in outpatient practice. Pharmateka 2017; 1: 38-45 [in Russian].
12. Vartanyan R.V., Sergeeva E.M., Cheshik S.G. Evaluation of therapeutic efficacy of Kagocel® preparation in children of early and preschool age with acute respiratory viral infections. Detskie infekcii 2011; 1: 36-41 [in Russian].
13. Kharlamova F.S., Kladova O.V., Sergeeva E.M., Shcherbakova A.A., Yablonskaya K.P., Legkova T.P. Clinical efficacy of Kagocel® preparation for Treatment of Influenza and ARVI in Children Aged 2 to 6 Years. Detskie infekcii 2010; 4: 34-41 [in Russian].
14. Merkulova L.N., Kolobukhina L.V., Kisteneva L.B., Isaeva E.I., Burtseva E. I., Lkyanova N.A. et al. The therapeutic efficacy of Kagocel in cases of uncomplicated influenza and influenza complicated by angina. Clinical Pharmacology and Therapy 2002; 11(5): 21-23 [in Russian].
15. Babachenko I.V., Sharipova E.V., Belikova T.L. Hospital and clinic-based approaches to the treatment of ARVI in children Medical advice 2017; 1: 94-99 [in Russian].
16. Ershov F. I., Narovlyansky A.N. Theoretical and applied aspects of the interferon system: to the 60th anniversary of the discovery of interferons. Problems of Virology 2018; 63 (1): 10-18 [in Russian].
17. ErshovF. I., Narovlyansky .A.N. Usage of inter¬feron inducers during viral infections. Problems of Virology 2015; 60 (2): 5-10 [in Russian].
18. Manual for non-clinic investigations of drugs. Part 1. M.: Grif and K. 2012; 944.
19. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloro¬quine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis 2020; Mar 9. pii: ciaa237. doi: 10.1093/cid/ciaa237
Review
For citations:
Loginova S.Ya., Shchukina V.N., Savenko S.V., Borisevich S.V. Antiviral Activity of Kagocel® in vitro Against Virus SARS-CoV-2. Antibiot Khimioter = Antibiotics and Chemotherapy. 2020;65(3-4):3-6. (In Russ.) https://doi.org/10.37489/0235-2990-2020-65-3-4-3-6
Views:
28929
Email this article 